Skip to content

Effect of AN-PEP Enzyme on Gluten Digestion in Gluten Sensitive Individuals

Effect of the Enzyme AN-PEP on Gluten Degradation in the Stomach of Gluten-sensitive Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02060864
Acronym
AN-PEP-03
Enrollment
18
Registered
2014-02-12
Start date
2014-04-30
Completion date
2015-08-31
Last updated
2015-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-coeliac Gluten Sensitivity

Keywords

enzyme, gluten, food intolerance

Brief summary

In this trial, the effect of a low and a high dose AN-PEP will be investigated in gluten sensitive individuals. Volunteers receive a breakfast with background (0.5 g) gluten. Capsules are taken in the morning within 5 min after start of breakfast. Gastrointestinal fluid will be sampled over 3 hours to measure gluten degradation. After 5 volunteers have completed 3 test days, a blind interim analysis is performed by a third party based on which it is decided whether to proceed with the low AN-PEP dose.

Interventions

DIETARY_SUPPLEMENTAN-PEP

Two pills are consumed in the morning with a breakfast

DIETARY_SUPPLEMENTPlacebo

Sponsors

DSM Food Specialties
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
Yes

Inclusion criteria

* Male/female * Age ≥18 but \<70 yr * Females: Hormonal contraceptive treatment * Self-reported gluten-sensitive individuals fulfilling the Rome III criteria while consuming gluten * Subject has read and understood the information provided on the study and given written informed consent

Exclusion criteria

* Coeliac disease serology while consuming gluten (serological test for tissue transglutaminase IgA antibodies and total IgA antibodies) * Wheat allergy (serological test for wheat protein IgE antibodies) * Medication or medical condition that affects gastric emptying or secretion * Females: Pregnancy or breast-feeding * Inability to swallow the gastroduodenal feeding tube * Any medical condition that in the opinion of the investigators may interfere with the study and may jeopardise the health status of the participant * Any condition that in the opinion of the investigators may interfere with the study and may jeopardise the health status of the participant

Design outcomes

Primary

MeasureTime frameDescription
Effect of 160.000 PPI AN-PEP on duodenal gluten3-hourEffect of AN-PEP (160.000 PPI) on gluten degradation based on amount of gluten detected in the duodenum compared with placebo over 180 min (Success is defined as at least 50% gluten degradation compared to placebo in an individual test, calculated using AUC)

Secondary

MeasureTime frameDescription
Effect of 80.000 PPI AN-PEP on duodenal gluten3-hourEffect of AN-PEP (80.000 PPI) on gluten degradation based on amount of gluten detected in the duodenum compared to placebo over 180 min (Success is defined as at least 50% gluten degradation compared to placebo in an individual test, calculated using AUC)
Effect of 80.000 PPI AN-PEP on gastric gluten AUC3-hourEffect of AN-PEP (80.000 PPI) on gluten degradation based on amount of gluten detected in the stomach compared to placebo over 180 min (Success is defined as at least 50% gluten degradation compared to placebo in an individual test, calculated using AUC)
Effect of 160.000 PPI AN-PEP on percentage duodenal gluten reduction3-hourThe average reduction in gluten concentration (as a continuous measure) following administration of AN-PEP (160.000 PPI) on gluten degradation (defined as the percentage of gluten degraded by 180 minutes) based on gluten detection in the duodenum compared with placebo over 180 min using AUC.
Effect of 160.000 PPI AN-PEP on gastric gluten3-hourEffect of AN-PEP (160.000 PPI) on gluten degradation based on amount of gluten detected in the stomach compared with placebo over 180 min (Success is defined as at least 50% gluten degradation compared to placebo in an individual test, calculated using AUC)
Effect of 80.000 PPI AN-PEP on percentage duodenal gluten reduction3-hourThe average reduction in gluten concentration (as a continuous measure) following administration of AN-PEP (80.000 PPI) on gluten degradation (defined as the percentage of gluten degraded by 180 minutes) based on gluten detection in the duodenum compared with placebo over 180 min using AUC.
Effect of 80.000 PPI AN-PEP on percentage gastric gluten reduction3-hourThe average reduction in gluten concentration (as a continuous measure) following administration of AN-PEP (low and high dose) on gluten degradation (defined as the percentage of gluten degraded by 180 minutes) based on gluten detection in the stomach compared with placebo over 180 min using AUC.
Effect of 160.000 PPI AN-PEP on percentage gastric gluten reduction3-hourThe average reduction in gluten concentration (as a continuous measure) following administration of AN-PEP (160.000 PPI) on gluten degradation (defined as the percentage of gluten degraded by 180 minutes) based on gluten detection in the stomach compared with placebo over 180 min using AUC.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026